Clinical Specialties is voluntarily recalling Avastin unit dose syringes. The product has or potentially could result in an infection within the eye. Clinical Specialties has received reports of five intraocular infections from physician’s offices and this is how the problem was identified.

The National Institute for Health and Clinical Excellence (NICE) has published draft guidance today (18 December) on the use of bevacizumab ( Avastin , Roche) as a treatment for women with advanced ovarian cancer. The draft guidance does not recommend the use of bevacizumab when used with paclitaxel and carboplatin for people with advanced disease, as a cost-effective treatment for the NHS. This draft guidance has now been issued for consultation: NICE has not yet published final guidance to the NHS. The Institute is aware that UK clinical practice is to prescribe bevacizumab at a d...

Roche announced that the European Commission has approved Avastin ( bevacizumab ) in combination with standard chemotherapy ( carboplatin and paclitaxel ) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer.